When an IVF cycle fails — particularly when it fails more than once — the most important decision a couple makes before the next attempt is not which clinic to go to, not which protocol to use, and not how many embryos to transfer. The most important decision is whether to investigate before trying again.
Investigation means testing — specifically, the advanced tests that go beyond the standard pre-IVF work-up and look at dimensions of fertility that routine assessment does not reach. These tests have names that are unfamiliar to most patients: ERA, PGT-A, sperm DNA fragmentation index, hysteroscopy, endometrial biopsy for chronic endometritis, immunological panels, thrombophilia screens. They represent a tier of diagnostic investigation that is available but is not routinely offered at most IVF clinics — either because of cost considerations, because of unfamiliarity with the evidence base, or because the clinic's operational model does not accommodate individualized investigation.
At Metro IVF in Ambikapur, these tests are not exotic additions to a basic protocol. They are the clinical standard for every patient who arrives with a history of IVF failure. Dr. Ashish Soni considers them not optional extras but essential components of the re-evaluation that every failed cycle deserves.
This article explains each of the most important advanced tests in plain language — what each test is, what it looks for, what its findings mean, who should have it, and what changes in treatment when it reveals something significant. It is written as a reference guide for couples planning an IVF retry who want to understand exactly what investigation is available and what each test can contribute to the success of their next attempt.
Why Standard Tests Are Not Enough After IVF Failure
The standard pre-IVF work-up — the tests performed before a first IVF cycle at most clinics — covers the essential baseline: a hormonal profile for the woman, a semen analysis for the man, a pelvic ultrasound, and in some clinics a basic assessment of tubal patency. These tests are appropriate for establishing eligibility for IVF. They are not designed to investigate why IVF has failed.
When IVF has failed once, the standard work-up has already been completed — and it did not prevent the failure. Repeating the same tests before a retry provides no new information. It confirms only that the baseline parameters remain what they were. It does not investigate the specific reasons the previous cycle failed, and it does not address the factors — many of which are not captured by standard testing — that may be contributing to repeated failure.
The advanced tests described in this article are the tools that fill this gap. They are the investigations that move beyond eligibility assessment into genuine diagnostic investigation — looking not at whether IVF is appropriate, but at why it has not worked, and what specifically needs to be different for it to work.
Test One: ERA — Endometrial Receptivity Analysis
What It Is
ERA — Endometrial Receptivity Analysis — is a test that assesses the receptivity of the uterine lining at the expected time of embryo transfer. Specifically, it examines the gene expression pattern of endometrial tissue — looking at the activity of 248 genes that together define whether the endometrium is in its receptive phase — and determines whether the endometrium is receptive, pre-receptive, or post-receptive at the time the biopsy is taken.
What It Looks For
Standard IVF practice assumes that the implantation window — the period during which the endometrium is capable of accepting an embryo — opens at a predictable time in all women. In frozen embryo transfer cycles using standard progesterone protocols, this window is assumed to occur approximately 120 hours after progesterone is initiated. Transfers are timed accordingly.
In most women, this assumption is correct. In a significant minority — studies suggest 20 to 30 percent of women with recurrent implantation failure — the window is displaced. Their endometrium becomes receptive earlier or later than the standard assumed timing, and transfers performed at the standard time consistently arrive when the endometrium is not yet ready or has already closed.
ERA identifies whether the window is displaced and, if so, by how many hours. When displacement is found, subsequent transfers are timed to the personalized receptive window identified by the ERA — a simple change in timing that produces significantly improved implantation rates in displaced-window patients.
Who Should Have It
ERA is most strongly indicated in women who have had two or more failed embryo transfers despite apparently good embryos and adequate endometrial thickness and pattern — particularly in frozen embryo transfer cycles where endometrial preparation is exogenously controlled. It is also considered in women with unexplained infertility who have never achieved implantation despite multiple transfers.
How It Is Performed
ERA requires an endometrial biopsy — a small sample of tissue taken from the uterine lining — performed in a mock transfer cycle that replicates the exact hormonal conditions of the planned transfer cycle, at the time the transfer would normally occur. The biopsy is sent for genomic analysis, and results are typically available within two to three weeks. A subsequent transfer cycle is then timed according to the ERA result.
What Changes When ERA Finds a Displaced Window
The transfer timing is adjusted — sometimes by as little as twelve hours, sometimes by twenty-four or forty-eight hours — to align with the personalized window. Studies consistently report significantly improved implantation rates in ERA-identified displaced-window patients when subsequent transfers are performed at the personalized time. The intervention is simple. The potential benefit is substantial.
Test Two: PGT-A — Preimplantation Genetic Testing for Aneuploidies
What It Is
PGT-A is a laboratory technique that examines the chromosomal content of embryos before transfer — identifying which embryos carry the correct number of chromosomes and which carry chromosomal abnormalities that would prevent viable pregnancy.
What It Looks For
Human embryos can carry chromosomal abnormalities — aneuploidies — in which one or more chromosomes are present in abnormal numbers. An embryo with trisomy 21, for example, carries three copies of chromosome 21 instead of two. Most aneuploidies are incompatible with pregnancy — embryos carrying them either fail to implant, implant briefly and result in early miscarriage, or in rare cases result in pregnancies with significant chromosomal conditions.
The critical clinical insight is that chromosomal abnormalities in embryos are invisible to standard morphological grading. An aneuploid embryo can look identical to a euploid embryo under the microscope. An embryologist grading embryos by appearance alone cannot distinguish between them. When aneuploid embryos are transferred without PGT-A screening, they fail — consistently and inevitably — regardless of how well prepared the uterus was or how excellent the morphology appeared.
PGT-A identifies euploid embryos — those with the correct chromosomal complement — before transfer, allowing only chromosomally normal embryos to be transferred. This eliminates chromosomal abnormality as a cause of transfer failure and significantly improves implantation rates and reduces miscarriage rates in cycles where euploid embryos are transferred.
Who Should Have It
PGT-A is most strongly indicated in women over 35, in couples with recurrent miscarriage, in couples with repeated implantation failure despite apparently good embryos, and in couples where prior cycles have produced multiple embryos but none have resulted in pregnancy. It is also considered in any couple where the history of failure suggests that chromosomal abnormality in the embryos may be a contributing factor.
How It Is Performed
PGT-A requires embryo biopsy — the removal of a small number of cells from the trophectoderm of a blastocyst, typically on day five or six of development. The biopsied cells are sent for chromosomal analysis — most commonly using next-generation sequencing, which can identify abnormalities in all twenty-three pairs of chromosomes simultaneously. The embryos are frozen while results are awaited, and only euploid embryos are selected for transfer in a subsequent frozen transfer cycle.
What PGT-A Does Not Do
PGT-A tests chromosomal number. It does not test for all possible genetic conditions — single-gene disorders require a different form of testing called PGT-M. It does not guarantee a successful pregnancy even from a euploid embryo — because implantation depends on uterine factors as well as embryo factors. And it reduces the number of embryos available for transfer — biopsied embryos that are aneuploid are not used, which in some cases means fewer embryos available in couples with limited embryo yield. These limitations are part of the honest clinical discussion that Dr. Soni has with every couple for whom PGT-A is being considered.
Test Three: Sperm DNA Fragmentation Index — DFI
What It Is
The DFI — DNA Fragmentation Index — is a measure of the proportion of sperm in a semen sample that carry significant damage to their genetic material. It is entirely separate from standard semen analysis and assesses a dimension of sperm quality that standard count, motility, and morphology measurements cannot detect.
What It Looks For
As the dedicated article on this topic in this series explained in detail, high sperm DNA fragmentation can cause fertilization to occur normally, embryos to develop apparently normally, and transfers to proceed — but implantation to fail repeatedly. The DNA damage within the sperm compromises embryo developmental competence in ways that are not visible under the microscope and that the egg's repair mechanisms cannot fully compensate for.
A DFI below 15 percent is considered low. Between 15 and 25 percent is moderate. Above 25 percent is high and associated with significantly impaired IVF outcomes. Above 30 percent is severe.
Who Should Have It
Every male partner of a couple with IVF failure — without exception, regardless of standard semen analysis results. A normal semen analysis does not exclude high DNA fragmentation. The two assessments measure completely different aspects of sperm quality, and the finding of normal count, motility, and morphology provides no information about DFI.
What Changes When DFI Is Elevated
When elevated DFI is identified, a targeted reduction strategy is implemented — antioxidant therapy, varicocele treatment where applicable, lifestyle modification, optimization of ejaculatory frequency, or testicular sperm extraction to bypass epididymal DNA damage accumulation. The lead time for these interventions to affect DFI is two to three months — one spermatogenesis cycle. Planning the next IVF attempt with this lead time in mind allows the intervention to take full effect before the next egg collection.
Test Four: Hysteroscopy — Direct Uterine Cavity Assessment
What It Is
Hysteroscopy is a procedure in which a thin, flexible camera is passed through the cervix into the uterine cavity, allowing direct visual examination of the endometrial surface, the cavity shape, and the tubal ostia.
What It Looks For
Hysteroscopy identifies structural abnormalities of the uterine cavity — polyps, submucosal fibroids, intrauterine adhesions, uterine septum, and abnormalities of the endometrial surface including signs of chronic endometritis. Many of these conditions are not reliably detected on standard pelvic ultrasound — they require direct visualization to be confidently identified or excluded.
Who Should Have It
Every woman with two or more failed IVF transfers who has not had hysteroscopy within the past twelve months — or who has had hysteroscopy but where the context has since changed. Hysteroscopy before the first IVF cycle is ideal but not universal. Before a retry, it is essential.
What Changes When Hysteroscopy Finds an Abnormality
Identified abnormalities — polyps, adhesions, fibroids, septum — are corrected through hysteroscopic surgery before any further transfer is attempted. The improvement in implantation rates following correction of cavity abnormalities is well documented and can be dramatic in cases where a significant abnormality was present and undetected throughout previous cycles.
Test Five: Endometrial Biopsy for Chronic Endometritis
What It Is
An endometrial biopsy taken specifically to assess for chronic endometritis — a low-grade, persistent inflammation of the endometrial lining — through histological examination and endometrial culture.
What It Looks For
Chronic endometritis is identified histologically by the presence of plasma cells in the endometrial tissue — cells that are not normally present in healthy endometrium and whose presence indicates a persistent inflammatory state. Endometrial culture identifies the specific organism responsible for the infection.
Who Should Have It
Women with repeated implantation failure — particularly those whose previous hysteroscopy appeared grossly normal but whose transfers have nonetheless failed consistently. Chronic endometritis can be present in the absence of visible hysteroscopic abnormality and requires biopsy for definitive diagnosis.
What Changes When Chronic Endometritis Is Confirmed
Targeted antibiotic therapy directed at the identified organism resolves the infection in most cases. A confirmatory biopsy following treatment confirms resolution before the next transfer is attempted. The evidence for improved implantation rates following successful treatment of chronic endometritis is robust — in affected patients, treatment before transfer is not optional. It is a prerequisite.
Test Six: Comprehensive Immunological and Thrombophilia Panel
What It Covers
The immunological and thrombophilia panel at Metro IVF covers antiphospholipid antibodies — anticardiolipin and anti-beta-2 glycoprotein-1 — lupus anticoagulant, thyroid antibodies, and inherited clotting disorders including Factor V Leiden, prothrombin gene mutation, protein C and S deficiency, antithrombin III deficiency, and MTHFR polymorphisms.
What It Looks For
Antiphospholipid syndrome — the most clinically important immunological cause of recurrent implantation failure and early pregnancy loss — promotes abnormal blood clotting that compromises the placental circulation necessary for early pregnancy to establish and sustain. Inherited thrombophilias have a similar mechanism of action. Both conditions are treatable — typically with low-dose aspirin and low-molecular-weight heparin — but only when identified.
Thyroid antibodies — anti-TPO and anti-thyroglobulin — are associated with reduced implantation rates and higher miscarriage rates even in women with clinically normal thyroid function. Their presence warrants monitoring and, in some cases, levothyroxine supplementation even when TSH is within the normal range.
Who Should Have It
Women with two or more failed transfers, women with a history of recurrent miscarriage, and women with any personal or family history of clotting disorders. In the context of three or more failed cycles, a complete immunological and thrombophilia screen is included as standard in the Metro IVF evaluation.
What Changes When Abnormalities Are Found
When antiphospholipid syndrome or thrombophilia is confirmed, anticoagulation therapy — low-dose aspirin initiated before transfer and low-molecular-weight heparin continued through the first trimester — is incorporated into the transfer protocol. When thyroid antibodies are present with borderline TSH, levothyroxine is considered. These interventions are straightforward to implement and have a meaningful evidence base for improving outcomes in affected patients.
Test Seven: Doppler Assessment of Uterine Blood Flow
What It Is
A Doppler ultrasound assessment of uterine artery blood flow — measuring the resistance index and pulsatility index of the uterine arteries, and assessing the subendometrial blood flow pattern — provides information about the adequacy of vascular delivery to the endometrium.
What It Looks For
Poor uterine blood flow — characterized by high resistance in the uterine arteries and sparse subendometrial vascularity — is associated with reduced endometrial receptivity and lower implantation rates. The endometrium requires not just adequate estrogen stimulation but adequate vascular delivery of oxygen and nutrients to develop the functional receptivity necessary for implantation.
Who Should Have It
Women with thin or poorly developing endometrium and women with repeated implantation failure where other investigations have not revealed a clear cause. Doppler assessment is performed as part of the standard endometrial monitoring at Metro IVF and is specifically evaluated in women with a history of failed transfers.
What Changes When Blood Flow Is Found to Be Poor
Interventions to improve uterine perfusion — low-dose aspirin, vaginal sildenafil, vitamin E, and pentoxifylline — are incorporated into the endometrial preparation protocol. These agents improve blood flow through different mechanisms and in combination have the strongest evidence base for improving endometrial development and receptivity in women with documented poor uterine perfusion.
Test Eight: Vitamin D and Comprehensive Nutritional Assessment
What It Covers
Serum 25-hydroxyvitamin D level, folate status, iron studies, and in some cases CoQ10 assessment and DHEA-S level constitute the nutritional component of the Metro IVF pre-retry evaluation.
What It Looks For
Vitamin D deficiency — extraordinarily prevalent in India — is associated with reduced implantation rates, poorer embryo quality, and higher miscarriage rates. The mechanism involves vitamin D's role in endometrial immune tolerance and follicular development. Correction of deficiency before the next cycle is a simple, inexpensive, and evidence-supported intervention.
Folate deficiency affects DNA synthesis and early embryo development. Iron deficiency affects endometrial development and overall systemic function. DHEA-S levels inform decisions about DHEA supplementation in low-ovarian-reserve patients, where it has a documented evidence base for improving egg numbers and quality.
What Changes When Deficiencies Are Identified
Targeted supplementation — at doses and durations appropriate to correct the identified deficiency within the lead time available before the next cycle — is prescribed. This is not a generic multivitamin recommendation. It is a specific supplementation plan based on actual measured deficiency levels and the time available before the planned retry.
Putting It All Together: The Metro IVF Advanced Testing Protocol
The tests described in this article are not administered indiscriminately. At Metro IVF, the decision about which advanced tests are most appropriate for a specific patient is made on the basis of the clinical history — the pattern of previous failures, the investigation already completed, the specific findings that suggested a particular avenue of investigation, and the clinical judgment of Dr. Soni applied to the totality of what the history reveals.
Not every patient needs every test. A woman whose previous cycles failed at the fertilization stage needs a different investigation from a woman whose embryos developed well but failed to implant. A couple whose previous ERA was normal does not need to repeat it. A man whose sperm DNA fragmentation was tested and found to be normal does not need retesting unless his circumstances have changed.
What every patient with a history of IVF failure needs is a doctor who reads their history carefully enough to know which tests are indicated, orders those tests and not unnecessary others, interprets the results in the context of the complete clinical picture, and designs a genuinely different protocol based on what the investigation reveals.
This is the clinical standard at Metro IVF. It is the standard that Dr. Ashish Soni has built his practice around — and it is the standard that has produced outcomes in patients with three, four, and five previous failed cycles at other clinics who arrived at Metro IVF carrying histories that were labeled, implicitly or explicitly, as exhausted.
They were not exhausted. The investigation was.
Your Next Step
If you are planning an IVF retry after one or more failed cycles and you want to ensure that the next attempt is preceded by the most thorough investigation available — not a repeat of the standard work-up that did not prevent the previous failure — a consultation with Dr. Ashish Soni at Metro IVF in Ambikapur is the right starting point.
He will review your complete history, identify which advanced tests are most relevant to your specific pattern of failure, conduct those tests as part of a structured and comprehensive evaluation, and design a retry protocol that is built specifically around what the evaluation finds.
The difference between a retry that is simply another attempt and a retry that is genuinely informed by the right investigation is the difference between repeating a failed experiment and finally approaching the problem with the tools it actually requires.
Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist
Planning an IVF retry? Make sure the right investigation comes first. Book your advanced evaluation consultation with Dr. Soni today — and give your next cycle the foundation it deserves.